N

Nektar Therapeutics

D
NKTR
USD
-0.105
(-8.2031%)
Market Closed
90,259.00
حجم التداول
-0.97
الربح لكل سهم
-
العائد الربحي
-1.305556
P/E
216,293,387.83
حجم السوق
اليوم
-8.2031%
1 اسبوع
-14.545%
1 شهر
-10.305%
6 اشهر
-34.358%
12 اشهر
134.953%
بداية السنة
106.140%
كل الوقت
-93.161%
avatar
sara abdelazim
عدد النقاط
112
عدد التوصيات
2

Title:
Nektar Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people.The group derives revenue from the United States and the Rest of the World.
هل تحتاج مساعدة او لديك استفسار؟